» Articles » PMID: 36851254

Identification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget

Abstract

Healthcare decision-makers face difficult decisions regarding COVID-19 booster selection given limited budgets and the need to maximize healthcare gain. A constrained optimization (CO) model was developed to identify booster allocation strategies that minimize bed-days by varying the proportion of the eligible population receiving different boosters, stratified by age, and given limited healthcare expenditure. Three booster options were included: B, costing US $1 per dose, B, costing US $2, and no booster (NB), costing US $0. B and B were assumed to be 55%/75% effective against mild/moderate COVID-19, respectively, and 90% effective against severe/critical COVID-19. Healthcare expenditure was limited to US$2.10 per person; the minimum expected expense using B B or NB for all. Brazil was the base-case country. The model demonstrated that B for those aged <70 years and B for those ≥70 years were optimal for minimizing bed-days. Compared with NB, bed-days were reduced by 75%, hospital admissions by 68%, and intensive care unit admissions by 90%. Total costs were reduced by 60% with medical resource use reduced by 81%. This illustrates that the CO model can be used by healthcare decision-makers to implement vaccine booster allocation strategies that provide the best healthcare outcomes in a broad range of contexts.

Citing Articles

The Knowledge and Application of Economics in Healthcare in a High-Income Country Today: The Case of Belgium.

Standaert B, Vandenberghe D, Connolly M, Hellings J J Mark Access Health Policy. 2024; 12(3):264-279.

PMID: 39315121 PMC: 11417786. DOI: 10.3390/jmahp12030021.

References
1.
Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

2.
Feikin D, Higdon M, Abu-Raddad L, Andrews N, Araos R, Goldberg Y . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022; 399(10328):924-944. PMC: 8863502. DOI: 10.1016/S0140-6736(22)00152-0. View

3.
Zhu Y, Liu S, Zhang D . Effectiveness of COVID-19 Vaccine Booster Shot Compared with Non-Booster: A Meta-Analysis. Vaccines (Basel). 2022; 10(9). PMC: 9504142. DOI: 10.3390/vaccines10091396. View

4.
Crown W, Buyukkaramikli N, Thokala P, Morton A, Sir M, Marshall D . Constrained Optimization Methods in Health Services Research-An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value Health. 2017; 20(3):310-319. DOI: 10.1016/j.jval.2017.01.013. View

5.
Shim E . Optimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea. J Clin Med. 2021; 10(4). PMC: 7914460. DOI: 10.3390/jcm10040591. View